Bionure

📍 Barcelona, Spain🗓 Founded 2009👥 9 employees💰 Last funded Mar 2019
Biotechnology Research🌐 bionure.com
Website LinkedIn
Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.
5
Total investors
3
Early stage
0
Mid stage
1
Late stage
2009
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Spain
4
United States
1
Investor activity2010–2019 · investors recorded per year
20102201112016120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Bionure?
Bionure has 5 investors on record on gritt.io, including 3 early-stage backers and 1 late-stage investors.
When did Bionure last raise funding?
The most recent investment in Bionure recorded on gritt.io was in March 2019.
When was Bionure founded?
Bionure was founded in 2009.
What industry is Bionure in?
Bionure operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Bionure based?
Bionure is headquartered in Barcelona, Spain.